The Texas A&M Health Science Center Institute of Biosciences and Technology (IBT) in Houston recently received an early translational research grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to move recent scientific breakthroughs from the laboratory into drug development for cancers with some of the greatest unmet medical need.
Cheryl Lyn Walker, Ph.D., director of the Texas A&M IBT, along with Peter Davies, Ph.D., M.D., and Vannakambodi Ganesh, Ph.D., both with the Texas A&M IBT, Shuxing Zhang, Ph.D., with the University of Texas MD Anderson Cancer Center and Scott Gilbertson, M.D., Ph.D., with the University of Houston, were awarded $1,999,979 as a collaborative team to translate their discoveries into new drugs for uterine and kidney cancer.
The three-year grant will allow the team to develop drugs that target a tumor suppressor protein, p27, as a new therapeutic approach to treat p27-deficient cancers, including endometrial carcinoma, renal cell carcinoma, and in the future, breast and prostate cancer.
Currently, no medicinal therapies exist for late stage p27-deficient cancers – specifically endometrial and kidney cancer – and low survival rates further emphasize the dire unmet medical need that the team hopes to overcome with new, effective therapeutics.
“For a number of years, we have known that p27 inhibits tumor growth, but only in the cell nucleus where it tells the cells to stop dividing,” Walker explained. “However, many cancers drive p27 out of the nucleus and into the cytoplasm, promoting tumor growth and making it very difficult to target for therapeutics.”
Walker and team are working on a therapeutic that will, for the first time, increase levels of this tumor suppressor protein in the nucleus, where it can stop the cancer growth, without increasing levels in the cytoplasm. Utilizing state-of-the-art technology housed the John S. Dunn Gulf Coast Consortium for Chemical Genomics at the Texas A&M IBT, the researchers are currently conducting high throughput screens, looking at hundreds of millions of cells and tens of millions of compounds to find molecules that can raise p27 in the nucleus without raising levels in the cytoplasm.
They have already identified several promising “hits” using this screening approach. As result of the CPRIT support, the team will move forward with the next generation of these compounds that will prove more effective and be better candidates for clinical drug development.
“This tumor suppressor protein has been a potential therapeutic target for at least a decade, but, until now, no one has figured out a way to very specifically increase p27 in the nucleus to block cancer growth,” Walker said. “CPRIT is providing support during this early, critical stage to translate our discovery into drug development, and move it forward into preclinical testing to combat cancer, support that is difficult if not impossible to get elsewhere.”
CPRIT’s product development grants expedite innovation by helping bridge the gap between promising new discoveries in cancer and commercial development.
#Prostatecancer risk factors include: -being over the age of 50 -family history -diet Learn more: https://t.co/PQ77F2XysX #CancerMoonshot #endcancer
CHI St. Luke's Health@CHI_StLukes
As we reflect this #MLKDay, we hope to continue his legacy through caring for our communities, helping our neighbors, and sharing his message with others. https://t.co/phuNnJeQWG
Veteran awaiting heart transplant sang to lift others https://t.co/iBWkXD2gAZ via #VAntagePoint
Inspired by the support she received during #uterinecancer treatment and a new perspective on life, Callie Glaves is exploring ways to give back to others: https://t.co/j51l5j8b2j @PamSolimanMD #gyncsm #endcancer
Today’s #VeteranOfTheDay is Marine Veteran Arthur Roland Keller, who served in a WWI machine gun battalion at the Battle of Soissons: https://t.co/zhtwsuYoDM
RT @RiceEngineering: Today we honor and celebrate the life and work of Dr. Martin Luther King Jr. so that we may keep his dream alive forev…
"Many older adults don't get needed cardiac rehab after a heart attack," says a new study. https://t.co/sIlmV5VCRd via @Reuters https://t.co/XbCCl5QHDF
Even though Dana was just three when she first arrived at TIRR Memorial Hermann for polio treatment, she remembers it clearly. Nearly five decades after her treatment as a child, Dana returned. Read why: https://t.co/PJ1jfOqn2O.
@totalq8y2 Hi there, please see our response to your direct message. Best wishes to you.
Harris Health System@harrishealth
A sliced apple versus a slice of apple pie. If it were a healthy choice contest, fresh fruit would certainly win. But many of us may find it hard to resist that sweet treat. To help you eat better, try the following simple steps. https://t.co/nAQHDZhmXI https://t.co/1AcQaEk6W8
In recognition of Dr. King’s incredible legacy of service and leadership to gain equality for all Americans, Congress designated #MLK federal holiday as a national day of service. #MLKDay is a chance to honor his life and re-commit ourselves to serving our communities. https://t.co/XbzfO3k6o8
University of Houston@UHouston
Campus is closed today in honor of #MLKDay. Celebrate Dr. King's life and legacy with UH: https://t.co/ZKWf16ih45 https://t.co/ZXdr2MFaN0
We will be closed tomorrow Monday, Jan. 20 in observance of Martin Luther King, Jr. Day. We will reopen Tuesday, Jan. 21. https://t.co/UtHKw8Ov6H
Are Juice Cleanses Actually Good for You? 🍎🍌🥑🥒🍋How fruits and veggies can be too much of a good thing.https://t.co/M05fuPhpcf https://t.co/lcKuO6eOJu
The flu season is only just ramping up. Here is what you need to know about this year's season. https://t.co/Yibv9afdxo #flu #fluseason